How to buy Tonix Pharmaceuticals Holding stock | $0.5848

Tonix Pharmaceuticals Holding Corp is a biotechnology business based in the US. Tonix Pharmaceuticals Holding shares (TNXP) are listed on the NASDAQ and all prices are listed in US Dollars. Tonix Pharmaceuticals Holding employs 26 staff and has a market cap (total outstanding shares value) of 0.00.

Tonix Pharmaceuticals Holding stock price (NASDAQ: TNXP)

Use our graph to track the performance of TNXP stocks over time.

Tonix Pharmaceuticals Holding shares at a glance

• Key figures

Information last updated 2021-10-16.

Latest market close	$0.58
52-week range	$0.51 - $2.12
50-day moving average	$0.62
200-day moving average	$0.93
Wall St. target price	$3.75
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.32

Buy Tonix Pharmaceuticals Holding shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Tonix Pharmaceuticals Holding stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Tonix Pharmaceuticals Holding price performance over time

Historical closes compared with the close of $0.5848 from 2021-10-20

1 week (2021-10-13)	4.43%
1 month (2021-09-21)	-2.53%
3 months (2021-07-21)	-44.30%
6 months (2021-04-21)	-42.67%

1 year (2020-10-20)	-16.92%
2 years (2019-10-18)	27.21%
3 years (2018-10-19)	0.72
5 years (2016-10-20)	0.6884

Tonix Pharmaceuticals Holding financials

Gross profit TTM	$0
Return on assets TTM	-37.03%
Return on equity TTM	-62.56%
Profit margin	0%
Book value	$0.52
Market capitalisation	$203.8 million

TTM: trailing 12 months

Shorting Tonix Pharmaceuticals Holding shares

There are currently 9.5 million Tonix Pharmaceuticals Holding shares held short by investors – that's known as Tonix Pharmaceuticals Holding's "short interest". This figure is 4.6% down from 9.9 million last month.

There are a few different ways that this level of interest in shorting Tonix Pharmaceuticals Holding shares can be evaluated.

Tonix Pharmaceuticals Holding's "short interest ratio" (SIR)

Tonix Pharmaceuticals Holding's "short interest ratio" (SIR) is the quantity of Tonix Pharmaceuticals Holding shares currently shorted divided by the average quantity of Tonix Pharmaceuticals Holding shares traded daily (recently around 11.8 million). Tonix Pharmaceuticals Holding's SIR currently stands at 0.8. In other words for every 100,000 Tonix Pharmaceuticals Holding shares traded daily on the market, roughly 800 shares are currently held short.

However Tonix Pharmaceuticals Holding's short interest can also be evaluated against the total number of Tonix Pharmaceuticals Holding shares, or, against the total number of tradable Tonix Pharmaceuticals Holding shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Tonix Pharmaceuticals Holding's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Tonix Pharmaceuticals Holding shares in existence, roughly 30 shares are currently held short) or 0.0265% of the tradable shares (for every 100,000 tradable Tonix Pharmaceuticals Holding shares, roughly 27 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Tonix Pharmaceuticals Holding.

Find out more about how you can short Tonix Pharmaceuticals Holding stock.

Tonix Pharmaceuticals Holding share dividends

We're not expecting Tonix Pharmaceuticals Holding to pay a dividend over the next 12 months.

Have Tonix Pharmaceuticals Holding's shares ever split?

Tonix Pharmaceuticals Holding's shares were split on a 1:10 basis on 31 October 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Tonix Pharmaceuticals Holding shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Tonix Pharmaceuticals Holding shares which in turn could have impacted Tonix Pharmaceuticals Holding's share price.

Tonix Pharmaceuticals Holding share price volatility

Over the last 12 months, Tonix Pharmaceuticals Holding's shares have ranged in value from as little as $0.51 up to $2.12. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tonix Pharmaceuticals Holding's is 1.2513. This would suggest that Tonix Pharmaceuticals Holding's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Tonix Pharmaceuticals Holding overview

Tonix Pharmaceuticals Holding Corp. discovers, acquires, develops, and licenses small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The company's lead vaccine candidate is TNX-1800, a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19. Its vaccines also comprise TNX-801, a live horsepox virus vaccine to protect against smallpox and monkeypox and serves as the vector platform; and TNX-2300 for the prevention of COVID-19. The company's lead CNS candidate is TNX-102 SL, a sublingual tablet formulation of cyclobenzaprine for fibromyalgia, and for the treatment of agitation in Alzheimer's disease, posttraumatic stress disorder (PTSD), and alcohol use disorder. Its products include TNX-1300 for the treatment of cocaine intoxication; TNX-601 CR for depression disorder, PTSD, and neurocognitive dysfunction from corticosteroids; and TNX-1900 for migraine and craniofacial pain treatment.

Frequently asked questions

What percentage of Tonix Pharmaceuticals Holding is owned by insiders or institutions?
Currently 0.066% of Tonix Pharmaceuticals Holding shares are held by insiders and 21.559% by institutions. How many people work for Tonix Pharmaceuticals Holding?
Latest data suggests 26 work at Tonix Pharmaceuticals Holding. When does the fiscal year end for Tonix Pharmaceuticals Holding?
Tonix Pharmaceuticals Holding's fiscal year ends in December. Where is Tonix Pharmaceuticals Holding based?
Tonix Pharmaceuticals Holding's address is: 26 Main Street, Chatham, NJ, United States, 07928 What is Tonix Pharmaceuticals Holding's ISIN number?
Tonix Pharmaceuticals Holding's international securities identification number is: US8902607063 What is Tonix Pharmaceuticals Holding's CUSIP number?
Tonix Pharmaceuticals Holding's Committee on Uniform Securities Identification Procedures number is: 890260102